Braveheart Bio IPO: $18 pricing on 2026-08-05
Braveheart Bio priced 21,250,000 shares at $18 in its dated 2026-08-05 announcement, with approximately $382.5 million base gross proceeds.
Dated offering terms — 2026-08-05
Braveheart Bio announced a price of $18 for 21,250,000 shares, representing about $382.5 million before fees. Its announcement expected Nasdaq Global Market trading under BRVE on 6 August 2026. Closing was expected on 7 August 2026, subject to conditions.
Braveheart develops therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. All base shares were company-issued. Underwriters received an option for 3,187,500 more shares. The gross base amount here is calculated as shares multiplied by price.
What the financing changes
In cardiovascular drug development, the eventual investment case depends on clinical benefit, safety and how a therapy fits into treatment practice. The financing provides resources to investigate those questions, without settling them. A meaningful follow-up should connect trial milestones to the cost and timing of obtaining evidence. Readers should also distinguish fresh capital raised by the company from later trading between investors. Only the former directly adds financing for the development business at the point of issuance.
The trading timetable above records the issuer's expectations at pricing; it is not a live market-price quotation.